#breakingbiotech

Hey everybody, I hope you've all been enjoying the holidays. I talk about 3 things in this video: The federal reserve and chairman Powell's comments on their guidance and the economy. DBVT pulling their

Biogen/Eisai to present updated subgroup analyses on their Phase 2 study looking at their Alzheimer's medicine, BAN2401. This antibody binds to amyloid beta protofibrils, reducing plaques in the brain.